In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

The company’s stock, currently trading at $529.24 ... Eylea has been a significant revenue driver for Regeneron, and its decline poses a substantial risk to the company’s financial performance.

The decision follows recent developments in Regeneron’s obesity treatment pipeline. Trading near its 52-week low of $481.58, the stock has seen a sharp 18.6% decline in the past week.

The stock market overreacts to news ... Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales. Overall, this quarter could ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic ...

REGN) stock, maintaining a $940 price target. The decision follows mixed Phase 3 results for itepekimab in chronic obstructive pulmonary disease (COPD), which contributed to a steep 16.7% decline in ...

This news led to a significant 19% decline in Regeneron’s stock price, which the analysts deemed disproportionate compared to consensus peak sales estimates for itepekimab of $2.7 billion. While the ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

The stock got hammered last week after REGN ... REGN’s shares have lost 31.7% compared with the industry’s 3.2% decline. Regeneron has a tough road ahead, as it will take a long time for ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...